| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9472395e6c6d2e1704509277e10dce5c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b6e0f9d8706e5e8d95f4f9e1d6628fd9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9811f3518401df34561aba94ae5fc959 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-08 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04 |
| filingDate |
2011-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92d419c8a03a6c84dfcb8bc6f4cacdb0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_39a969ab1af690811bb83317cf6b6fbf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0e8995415beae2d4dca4056971bc23c |
| publicationDate |
2012-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2012071412-A1 |
| titleOfInvention |
Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders |
| abstract |
The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective agonists of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Such compounds are useful as medicaments for treatment and prevention of a range of medical conditions characterized by disturbed gastrointestinal motility including, but not limited to, post-surgical gastroparesis and post-operative ileus in combination with opioid-induced bowel dysfunction. These agents are effective for multiple disorders at dose levels equivalent to those required to treat a single disorder. |
| priorityDate |
2006-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |